KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) FCF Margin (2018 - 2025)

Castle Biosciences' FCF Margin history spans 7 years, with the latest figure at 23.03% for Q4 2025.

  • For Q4 2025, FCF Margin fell 702.0% year-over-year to 23.03%; the TTM value through Dec 2025 reached 15.4%, down 413.0%, while the annual FY2025 figure was 15.4%, 413.0% down from the prior year.
  • FCF Margin for Q4 2025 was 23.03% at Castle Biosciences, down from 30.11% in the prior quarter.
  • Across five years, FCF Margin topped out at 42.14% in Q3 2024 and bottomed at 79.93% in Q1 2022.
  • The 5-year median for FCF Margin is 13.94% (2022), against an average of 8.4%.
  • The largest annual shift saw FCF Margin tumbled -13745bps in 2021 before it surged 4655bps in 2024.
  • A 5-year view of FCF Margin shows it stood at 24.26% in 2021, then fell by -13bps to 27.39% in 2022, then surged by 132bps to 8.87% in 2023, then skyrocketed by 239bps to 30.05% in 2024, then dropped by -23bps to 23.03% in 2025.
  • Per Business Quant, the three most recent readings for CSTL's FCF Margin are 23.03% (Q4 2025), 30.11% (Q3 2025), and 19.97% (Q2 2025).